Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy
出版年份 2019 全文链接
标题
Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy
作者
关键词
-
出版物
JOURNAL OF CELLULAR PHYSIOLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2019-10-01
DOI
10.1002/jcp.29216
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Mast Cells: A Double-Edged Sword in Cancer
- (2019) Afshin Derakhshani et al. IMMUNOLOGY LETTERS
- Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance
- (2019) Zohreh Rezaei et al. DNA AND CELL BIOLOGY
- Interactions between cancer stem cells, immune system and some environmental components: Friends or foes?
- (2019) Fatemeh Vahidian et al. IMMUNOLOGY LETTERS
- Dynamic miRNA activity identifies therapeutic targets in trastuzumab-resistant HER2+ breast cancer
- (2018) Joseph T. Decker et al. BIOTECHNOLOGY AND BIOENGINEERING
- Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer
- (2018) Philip E. Lammers et al. BRITISH JOURNAL OF CANCER
- Treatment of advanced HER2-positive breast cancer: 2018 and beyond
- (2018) Noam Pondé et al. CANCER TREATMENT REVIEWS
- p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial
- (2018) Jeff Sperinde et al. CLINICAL CANCER RESEARCH
- Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study
- (2018) Martin Filipits et al. CLINICAL CANCER RESEARCH
- Metformin-induced caveolin-1 expression promotes T-DM1 drug efficacy in breast cancer cells
- (2018) Yuan-Chiang Chung et al. Scientific Reports
- HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer
- (2018) Alexandra Canonici et al. INVESTIGATIONAL NEW DRUGS
- Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
- (2018) Babak Nami et al. Cancers
- PF-05280014: A Trastuzumab Biosimilar
- (2018) Julia Paik BIODRUGS
- PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study
- (2018) Mark D. Pegram et al. BRITISH JOURNAL OF CANCER
- Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study
- (2018) Takamasa Koga et al. LUNG CANCER
- p95HER2–T cell bispecific antibody for breast cancer treatment
- (2018) Irene Rius Ruiz et al. Science Translational Medicine
- Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy
- (2018) Patrícia M. R. Pereira et al. Nature Communications
- SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression
- (2017) Gulden Menderes et al. GYNECOLOGIC ONCOLOGY
- Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)
- (2017) Matthew Sung et al. MOLECULAR CANCER THERAPEUTICS
- A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
- (2017) Ji-Youn Han et al. Cancer Research and Treatment
- Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)
- (2017) S. Modi et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer
- (2016) An Na Seo et al. BRITISH JOURNAL OF CANCER
- Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry
- (2016) Yunting Zhu et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity
- (2016) Gábor Tóth et al. mAbs
- Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation
- (2016) Marina Saisana et al. Oncotarget
- Identification of KLK10 as a therapeutic target to reverse trastuzumab resistance in breast cancer
- (2016) Zhuo Wang et al. Oncotarget
- Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
- (2015) Eunhee G. Kim et al. Biomolecules & Therapeutics
- Bispecific antibodies
- (2015) Roland E. Kontermann et al. DRUG DISCOVERY TODAY
- The expression difference of insulin-like growth factor 1 receptor in breast cancers with or without diabetes
- (2015) Liu Ji-Yan et al. Journal of Cancer Research and Therapeutics
- The canonical Wnt pathway regulates the metastasis-promoting mucin MUC4 in pancreatic ductal adenocarcinoma
- (2015) Priya Pai et al. Molecular Oncology
- β2-AR signaling controls trastuzumab resistance-dependent pathway
- (2015) D Liu et al. ONCOGENE
- Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer
- (2014) Jetzabel García-Parra et al. EUROPEAN JOURNAL OF CANCER
- The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
- (2013) S. Muenst et al. BREAST CANCER RESEARCH AND TREATMENT
- A systematic review of dual targeting in HER2-positive breast cancer
- (2013) Iben Kümler et al. CANCER TREATMENT REVIEWS
- Basal/HER2 breast carcinomas
- (2013) Begoña Martin-Castillo et al. CELL CYCLE
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells
- (2013) D Raina et al. ONCOGENE
- Src activation by β-adrenoreceptors is a key switch for tumour metastasis
- (2013) Guillermo N. Armaiz-Pena et al. Nature Communications
- A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
- (2012) Nancy U. Lin et al. BREAST CANCER RESEARCH AND TREATMENT
- Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
- (2012) R Y Tsang et al. BRITISH JOURNAL OF CANCER
- Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
- (2012) Sandhya Girish et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study
- (2012) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches
- (2012) D W Kufe ONCOGENE
- Hsp90 inhibitors and drug resistance in cancer: The potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs
- (2011) Xiangyi Lu et al. BIOCHEMICAL PHARMACOLOGY
- Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer
- (2011) E. Razis et al. BREAST CANCER RESEARCH AND TREATMENT
- Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
- (2011) P Todeschini et al. BRITISH JOURNAL OF CANCER
- Treatment of HER2-positive breast cancer: current status and future perspectives
- (2011) Carlos L. Arteaga et al. Nature Reviews Clinical Oncology
- HER2 Therapy — An Abundance of Riches
- (2011) William J. Gradishar NEW ENGLAND JOURNAL OF MEDICINE
- Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+breast cancer patients
- (2011) Maurizio Scaltriti et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade
- (2010) Jianhui Ma et al. JOURNAL OF CLINICAL INVESTIGATION
- Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
- (2010) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
- (2010) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
- (2010) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Unveiling the role of network and systems biology in drug discovery
- (2010) Albert Pujol et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
- (2009) Teemu T. Junttila et al. CANCER CELL
- Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
- (2009) W. Scheuer et al. CANCER RESEARCH
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2009) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth
- (2009) S Chandarlapaty et al. ONCOGENE
- Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase
- (2009) E. S. Ehrlich et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840
- (2008) Andrew D. Seidman et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2Status and Benefit from Adjuvant Trastuzumab in Breast Cancer
- (2008) Soonmyung Paik et al. NEW ENGLAND JOURNAL OF MEDICINE
- HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion
- (2008) H Korkaya et al. ONCOGENE
- Development and application of Hsp90 inhibitors
- (2007) D SOLIT DRUG DISCOVERY TODAY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More